Skip to main content

Advertisement

SpringerLink
Log in

Treatment of primary sclerosing cholangitis

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Aims of treatment for primary sclerosing cholangitis are as follows: prevention of progression of hepatobiliary disease, reduction of symptoms and consequences of cholestasis (pruritus, osteoporosis), and prevention of complications (colorectal cancer, hepatobiliary cancer). Ursodeoxycholic acid (UDCA) improves biliary secretion and laboratory parameters of cholestasis, but its effects on liver histology and survival are not clear. It reduces the incidence of dysplasias and carcinomas of the colon in patients with colitis and possibly has a beneficial effect on the incidence of bile duct carcinomas. At present, UDCA represents the most promising therapeutic option. Immunosuppressive treatment has not been proven to be effective; it appears to be indicated in the overlap syndrome with autoimmune hepatitis but may be harmful in bacterial cholangitis. Bacterial cholangitis is common in patients with dominant stenoses and requires antibiotic treatment. Endoscopic treatment of dominant stenoses improves cholestasis and prolongs survival in comparison to predicted survival. Pruritus represents a problem in some patients, and cholestyramine represents the first-line treatment. If ineffective, opioid antagonists, rifampin, or ondansetron may be tried. For treatment of osteoporosis and osteopenia, calcium and vitamin D supplementation are recommended, and in selected cases, bisphosphonates may be indicated. In patients with severe cholestasis and coagulation defects, parenteral supplementation of vitamin K may be indicated. During treatment, all patients should be regularly screened for colonic and bile duct carcinomas. Patients with cirrhosis of the liver and its complications are treated accordingly, and in end-stage disease, liver transplantation is indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chapman RW, Arborgh BA, Rhodes JM, et al.: Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980, 21:870–877.

    Article  PubMed  CAS  Google Scholar 

  2. Wiesner RH, Grambsch PM, Dickson ER, et al.: Natural history, prognostic factors, and survival analysis. Hepatology 1989, 10:430–436.

    Article  PubMed  CAS  Google Scholar 

  3. Broome U, Olson R, Lööf L, et al.: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610–615.

    Article  PubMed  CAS  Google Scholar 

  4. Olsson R, Danielsson A, Järnebrot G, et al.: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991, 100:1319–1323.

    PubMed  CAS  Google Scholar 

  5. Pohl J, Ring A, Stremmel W, Stiehl A: The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006, 18:69–74.

    Article  PubMed  Google Scholar 

  6. Bergquist A, Ekbom A, Olsson R, et al.: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321–327.

    Article  PubMed  Google Scholar 

  7. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al.: Value of brush border cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999, 31:305–309.

    Article  PubMed  CAS  Google Scholar 

  8. Hultcrantz R, Olsson R, Danielsson A, et al.: A three year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999, 30:669–673.

    Article  PubMed  CAS  Google Scholar 

  9. Petersen-Benz C, Stiehl A: Impact of dominant stenoses on the serum level of the tumour marker Ca 19-9 in patients with primary sclerosing cholangitis [in German]. Z Gastroenterol 2005, 43:587–590.

    Article  PubMed  CAS  Google Scholar 

  10. Burak K, Angulo P, Pasha TM, et al.: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523–526.

    Article  PubMed  Google Scholar 

  11. Broome U, Löfberg R, Veress B, Erikson LS: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404–1408.

    PubMed  CAS  Google Scholar 

  12. Uehara T, Hamano H, Kawa S, et al.: Distinct clinico-pathological entity ‘autoimmune pancreatitis-associated sclerosing cholangitis’. Pathol Int 2005, 55:405–411.

    Article  PubMed  Google Scholar 

  13. Engler S, Elsing C, Flechtenmacher C, et al.: Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorder. Gut 2003, 52:688–689.

    Article  PubMed  CAS  Google Scholar 

  14. Stiehl A, Walker S, Stiehl L, et al.: Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57–64.

    Article  PubMed  CAS  Google Scholar 

  15. Beuers U, Spengler U, Kruis W, et al.: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology 1992, 16:707–714.

    Article  PubMed  CAS  Google Scholar 

  16. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691–695.

    Article  PubMed  CAS  Google Scholar 

  17. Mitchell SA, Bansi D, Hunt N, et al.: A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900–907.

    Article  PubMed  CAS  Google Scholar 

  18. Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558–1562.

    Article  PubMed  CAS  Google Scholar 

  19. Olsson R, Boberg KM, Schaffalisky de Muckadell O, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464–1472.

    Article  PubMed  CAS  Google Scholar 

  20. Sauer P, Benz C, Rudolph G, et al.: Influence of cholestasis on absorption of ursodeoxycholic acid. Dig Dis Sci 1999, 44:817–822.

    Article  PubMed  CAS  Google Scholar 

  21. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A: Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004, 40:693–698.

    Article  PubMed  CAS  Google Scholar 

  22. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A: Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. Dig Dis Sci 2006, 51:618–622.

    Article  PubMed  CAS  Google Scholar 

  23. Cullen SN, Chapman RW: The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006, 26:52–61.

    Article  PubMed  CAS  Google Scholar 

  24. Earnest DL, Holubec H, Wali RK, et al.: Chemoprevention of azomethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994, 54:5071–5074.

    PubMed  CAS  Google Scholar 

  25. Stiehl A, Raedsch R, Rudolph G: Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology 1988, 94:1201–1206.

    PubMed  CAS  Google Scholar 

  26. Tung BY, Emond MJ, Haggitt RC, et al.: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89–95.

    PubMed  CAS  Google Scholar 

  27. Pardi DS, Loftus EV, Kremers WK, et al.: Ursodeoxycholic acid as a chemoprotective agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889–893.

    Article  PubMed  CAS  Google Scholar 

  28. Wolf JM, Rybicki LA, Lashner BA: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783–788.

    Article  PubMed  CAS  Google Scholar 

  29. Stiehl A, Rudolph G, Kloeters-Plachky P, et al.: Development of bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002, 36:151–156.

    Article  PubMed  Google Scholar 

  30. Brandsaeter B, Isoniemi H, Broome U, et al.: Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815–822.

    Article  PubMed  CAS  Google Scholar 

  31. Boberg KM, Egeland T, Schrumpf E: Long-term effect of corticoid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003, 38:991–995.

    Article  PubMed  CAS  Google Scholar 

  32. Olsson R, Björnsson E, Bäckman L, et al.: Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998, 28:426–432.

    Article  PubMed  CAS  Google Scholar 

  33. Färkkilä M, Karvonen AL, Nurmi H, et al.: Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004, 40:1379–1386.

    Article  PubMed  CAS  Google Scholar 

  34. Kulaksiz H, Rudolph G, Kloeters-Plachky P, et al.: Biliary candida infections in primary sclerosing cholangitis. J Hepatol 2006, 45:711–716.

    Article  PubMed  Google Scholar 

  35. Ghent CN, Carruthers SG: Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988, 94:488–493.

    PubMed  CAS  Google Scholar 

  36. Podesta A, Lopez P, Terg R, et al.: Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991, 36:216–220.

    Article  PubMed  CAS  Google Scholar 

  37. Bachs L, Pares A, Elena M, et al.: Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992, 102:2077–2080.

    PubMed  CAS  Google Scholar 

  38. Bergasa NV, Talbot TL, Alling DW, et al.: A controlled trial of naloxone infusions for the prurittus of chronic cholestasis. Gastroenterology 1992, 102:544–549.

    PubMed  CAS  Google Scholar 

  39. Bergasa NV, Schmitt JM, Talbot TL, et al.: Open-label trial of oral nalmefene therapy for pruritus of cholestasis. Hepatology 1998, 27:679–684.

    Article  PubMed  CAS  Google Scholar 

  40. Wolfhagen FH, Sternieri E, Hop WC, et al.: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264–1269.

    Article  PubMed  CAS  Google Scholar 

  41. Muller C, Pongratz S, Pidlich J, et al.: Treatment of pruritus in chronic liver disease with 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998, 10:865–870.

    Article  PubMed  CAS  Google Scholar 

  42. Grijm R, Huibregtse K, Bartelsman J, et al.: Therapeutic investigations in primary sclerosing cholangitis. Dig Dis Sci 1986, 31:792–798.

    Article  PubMed  CAS  Google Scholar 

  43. Johnson GK, Geenen JE, Venu RP, Hogan WJ: Endoscopic treatment of biliary duct strictures in sclerosing cholangitis: follow-up assessment of a new therapeutic approach. Gastrointest Endosc 1987, 33:9–12.

    Article  PubMed  CAS  Google Scholar 

  44. Lee JG, Schutz SM, England RE, et al.: Endoscopic therapy of sclerosing cholangitis. Hepatology 1995, 21:661–667.

    PubMed  CAS  Google Scholar 

  45. Van Milligen de Wit AW, van Bracht J, Rauws EA, et al.: Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996, 44:293–299.

    Article  PubMed  Google Scholar 

  46. Stiehl A, Rudolph G, Sauer P, et al.: Efficacy of ursodeoxycholic acid and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997, 26:560–566.

    Article  PubMed  CAS  Google Scholar 

  47. Ponsioen CY, Lam K, van Milligen de Wit AW, et al.: Four years experience with short-term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999, 94:2403–2407.

    Article  PubMed  CAS  Google Scholar 

  48. Kaya M, Petersen BT, Angulo P, et al.: Balloon dilatation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1059–1066.

    Article  PubMed  CAS  Google Scholar 

  49. Baluyut AR, Sherman S, Lehman GA, et al.: Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001, 53:308–312.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Heidelberg, Medizinische Universitätsklinik, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Adolf Stiehl

Authors
  1. Daniel Rost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hasan Kulaksiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adolf Stiehl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adolf Stiehl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rost, D., Kulaksiz, H. & Stiehl, A. Treatment of primary sclerosing cholangitis. Curr Treat Options Gastro 10, 111–119 (2007). https://doi.org/10.1007/s11938-007-0063-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-007-0063-6

Keywords

Search

Navigation